Product Licensing

Inovio Biomedical grants VGX Pharmaceuticals license to develop cancer therapeutic

Published in Proteomics Weekly, December 11th, 2006

Inovio Biomedical Corp. (INO), a company engaged in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced it has granted VGX Pharmaceuticals a worldwide nonexclusive license to its DNA delivery technology for intratumoral delivery of a proprietary gene to control the growth of melanoma and other cancers.

Under the terms of the agreement, Inovio will receive from VGX an upfront license fee and payments based on successful completion of clinical and regulatory milestones. Inovio will exclusively supply VGX with electroporation devices for the therapy included in the license agreement and will receive royalties on the sale of products...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2006-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry